Oncology

Advanced ROS1-positive NSCLC

Expert Roundtables Podcast: Next-Generation Tyrosine Kinase Inhibitors for ROS1-Positive Non–Small Cell Lung Cancer

expert roundtables by D. Ross Camidge, MD, PhD; Mark A. Socinski, MD; Heather Wakelee, MD, FASCO

Overview

<p>Although currently available ROS1 TKIs demonstrate high response rates for non–small cell lung cancer, some limitations do exist, including acquired resistance, central nervous system penetrance, and drug-related toxicities. In today’s podcast, our experts discuss recent data on next-generation TKIs and the trajectory of TKI therapy for this patient population.</p> <p> </p> <p><iframe title="Expert Perspectives® in Advanced ROS1-positive NSCLC Podcast 2025" width="500" height="281" src="https://www.youtube.com/embed/DanKg1RfA1Y?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe></p>

References

Boulanger MC, Schneider JL, Lin JJ. Advances and future directions in ROS1 fusion-positive lung cancer. Oncologist. 2024;29(11):943-956. doi:10.1093/oncolo/oyae205

Desilets A, Repetto M, Yang SR, Drilon A. Targeting ROS1 rearrangements in non–small cell lung cancer: current insights and future directions. Cancer. 2025;131(suppl 1):e35784. doi:10.1002/cncr.35784

Drilon A, Jenkins C, Iyer S, Schoenfeld A, Keddy C, Davare MA. ROS1-dependent cancers – biology, diagnostics and therapeutics. Nat Rev Clin Oncol. 2021;18(1):35-55. doi:10.1038/s41571-020-0408-9

Fabbri L, Di Federico A, Astore M, et al. From development to place in therapy of lorlatinib for the treatment of ALK and ROS1 rearranged non-small cell lung cancer (NSCLC). Diagnostics (Basel). 2023;14(1):48. doi:10.3390/diagnostics14010048

Gendarme S, Bylicki O, Chouaid C, Guisier F. ROS-1 fusions in non-small-cell lung cancer: evidence to date. Curr Oncol. 2022;29(2):641-658. doi:10.3390/curroncol29020057

Horton C, Hoang L, Zimmermann H, et al. Diagnostic outcomes of concurrent DNA and RNA sequencing in individuals undergoing hereditary cancer testing. JAMA Oncol. 2024;10(2):212-219. doi:10.1001/jamaoncol.2023.5586

Patil T, Smith DE, Bunn PA, et al. The incidence of brain metastases in stage IV ROS1-rearranged non–small cell lung cancer and rate of central nervous system progression on crizotinib. J Thorac Oncol. 2018;13(11):1717-1726. doi:10.1016/j.jtho.2018.07.001

Pérol M, Li W, Lai RK, Zhou C. Reply to: “Baseline brain metastasis imbalance in TRUST: implications for interpreting intracranial efficacy of taletrectinib” and “Taletrectinib in ROS1 fusion–positive non–small cell lung cancer: promising yet premature?” J Clin Oncol. 2025;43(29):3227-3228. doi:10.1200/JCO-25-01448

Rothschild SI, Mauti LA. ROS1 fusion-positive non-small cell lung cancer—repotrectinib as a new treatment option. Transl Cancer Res. 2025;14(6):3272-3276. doi:10.21037/tcr-2025-263

Wolf J, Goring S, Lee A, et al. Population-adjusted indirect treatment comparisons of repotrectinib among patients with ROS1+ NSCLC. Cancers (Basel). 2025;17(5):748. doi:10.3390/cancers17050748

Profile

D. Ross Camidge, MD, PhD

Director, Thoracic Oncology
Joyce Zeff Chair in Lung Cancer Research
University of Colorado Cancer Center
Aurora, CO

Profile

Mark A. Socinski, MD

Executive Medical Director
AdventHealth Cancer Institute
Orlando, FL

Profile

Heather Wakelee, MD, FASCO

Winston Chen and Phyllis Huang Professor
Professor of Medicine and Chief, Division of Oncology
Stanford University School of Medicine
Deputy Director
Stanford Cancer Institute
Stanford, CA

Oncology

Advanced ROS1-positive NSCLC

Expert Roundtables Podcast: Next-Generation Tyrosine Kinase Inhibitors for ROS1-Positive Non–Small Cell Lung Cancer

D. Ross Camidge, MD, PhD

Mark A. Socinski, MD

Heather Wakelee, MD, FASCO

Explore More in Advanced ROS1-positive NSCLC

Molecular Testing in Advanced Non–Small Cell Lung Cancer: Detecting Complex Rearrangements

From Mutation to Decision: Personalized Care Choices in Advanced ROS1-Positive Non–Small Cell Lung Cancer

The Biology and Clinical Course of Advanced ROS1-Positive Non–Small Cell Lung Cancer

Choosing Treatment for Brain Metastases in ROS1-Altered Non–Small Cell Lung Cancer